Neutralizing Antibody Discovery Platform

Creative Biolabs is dedicated to delivering highly efficient and precise solutions for the discovery of neutralizing antibodies to esteemed clients across the globe. Our state-of-the-art neutralizing antibody discovery platform positions us as a formidable partner in the realm of neutralizing antibody research.

Exceptional Neutralizing Antibody Discovery Platform

Our exceptional neutralizing antibody discovery platform specializes in a unique class of antibodies designed to specifically target and neutralize bacterial toxins, pathogens, and their derivatives. In response to the latest demands in immunodiagnosis and disease intervention research, our cutting-edge neutralizing antibody discovery platform offers an array of comprehensive and unparalleled services:

  • Harnessing a robust antibody discovery platform, we provide diverse technical services tailored to specific requirements, encompassing hybridoma, phage display, antibody humanization, and single B cell screening.
  • Our team of seasoned antibody researchers delivers dependable antibody discovery solutions, underpinned by standardized operating procedures that guarantee a success rate exceeding 99%.
  • Our integrated service process spans from antigen preparation to library construction, antibody screening, and immune potency monitoring, ensuring a seamless and thorough approach.
  • We possess the capability to offer comprehensive value-added services for antibodies, including labeling, pairing selection screening, kit development, and immunological detection.

Determinants of neutralizing antibodies. (Irene, 2019)Fig.1 Determinants of neutralizing antibodies. 1

Streamlined Workflow

We have established standardized processes for neutralizing antibody development, meticulously tailored to meet the swift turnaround and high-quality output requirements across diverse targets.

Workflow. (Creative Biolabs Original)Fig.2 Workflow.

Key Features

Our unbeatable advantages lie in our neutralizing antibody discovery platform:

  • Low endotoxin levels: Mitigating toxicity while facilitating Fc signal transduction, enabling integration of a broader spectrum of immune responses.
  • Rapid antibody development technology: Ensuring the swiftest delivery cycle and upholding the most stringent quality management standards.
  • Diverse antigen/antibody libraries: Boasting abundant antigen-antibody sequence resources that spearhead the initial stages of research.
  • High-throughput screening: Proficiency in processing large-scale samples and accommodating flexible preparations ranging from μg to g levels.

Published Data

Title: Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking

Research Objective:

Study aimed to develop rapid identification and development technology for effective neutralizing antibodies in response to the widespread outbreak of SARS-CoV-2 or any potential large-scale infectious diseases in the future.

Research Methods:

To surmount the limitations of traditional antigen recognition and antibody screening, researchers pioneered the LIBRA-seq technology utilizing DNA barcode antigens. This technology translates antigen-ligand interactions into sequenced events, enabling high-throughput sequencing to furnish experimental information on antigen recognition and corresponding ligand blocking across numerous B cells.

Research Findings:

The study successfully identified potent neutralizing antibodies against SARS-CoV-2, underscoring the efficacy of LIBRA-seq as an antibody screening tool. This groundbreaking screening method offers more comprehensive coverage of antibody epitopes, and its universal application can be extended to virtually any field of biological product development predicated on antigen-ligand interactions.

Antibody discovery. (Shiakolas, 2022)Fig.3 Antibody discovery.2

Our Products Data

Creative Biolabs has developed a series of neutralizing antibodies. Our NAbs exhibited good neutralizing activity and blocked the target protein binding to its ligands. The neutralization or blocking activity of these NAbs were validated by cell-based bioassays or other applications such as competitive ELISA.

PD-L1 binding to PD-1 was blocked by anti-PD-1 antibodies (Cat# V3S-0622-YC5183, V3S-1022-YC6030). (Creative Biolabs Original)Fig.4 PD-L1 binding to PD-1 was blocked by anti-PD-1 antibodies (Cat# V3S-0622-YC5183, V3S-1022-YC6030).

Our Services

Creative Biolabs will utilize our professional biological knowledge to ensure that our neutralizing antibody development platform produces excellent antibodies that meet your requirements with high specificity and low endotoxin levels. We encourage you to promptly reach out to us for the most robust technical platform available.


  1. Irene, Claus, et al. " Correlates of broadly neutralizing antibody development." Current Opinion. 14 (2019): 279-285.
  2. Shiakolas, Kramer, et al. " Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. " Nature Biotechnology. 40 (2022): 1270-1275.
For research use only, not directly for clinical use.
banner banner
© 2024 Creative Biolabs. All Rights Reserved.
Online Inquiry